ESP webinar on Solid Tumours (Abnostic) Biomarker Testing

The development of novel treatment options has allowed the design of potential agnostic therapeutic strategies for solid tumours. Those are based on detecting several biomarkers like HER2 overexpression, MMR proteins, NTRK Gene Fusions, BRAF V600E mutations and more.

The novel approach has application to cancers like breast, lung, and more.

Recently, there was a positive view from EMA/ CHMP, and in specific for HER2-positive (immunohistochemistry [IHC] 3+), signalling the importance of updating the medical community on this subject.

This webinar will present the role of pathology in tumour agnostic testing, the potential pitfalls, and how to use the newest scientific developments in the field for optimal cancer patient management.

The organisation of the webinar is supported by Daiichi Sankyo Europe GmbH